Evidence map›Paper›PMID 35316583›Full record

ReviewCurrent protocols2022

Validation-Based Insertional Mutagenesis (VBIM), A Powerful Forward Genetic Screening Strategy.

Sarmishtha De, Ilaria Tamagno, George R Stark, Mark W Jackson

Open access · greenAbstract readReview
In one paragraph

Review in Current protocols, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Sarmishtha DeDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Ilaria TamagnoDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio.
George R StarkDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Mark W JacksonDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Case Western Reserve University · USCleveland Clinic Lerner College of Medicine · US

Funding

TELOMERASE INACTIVATION BY RNASE L SIGNALS CELL DEATHP01CA062220 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI LI, XIAOXIA, STARK, GEORGE ROBERT · 1994 to 2020
$35.6M
Targeting Oncostatin M-Receptor to Suppress Metastasis and Therapy FailureR01CA252224 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI JACKSON, MARK W. · 2021 to 2025
$2.0M
NCI NIH HHS P01 CA062220NCI NIH HHS R01 CA252224NIH HHS P01CA062220NIH HHS R01CA252224NIH HHS W81XWH-18-1-0552
6 · The paper itself

Abstract

Forward genetics begins with a biological phenotype and attempts to identify genetic changes that influence that phenotype. These changes can be induced in a selected group of genes, for instance, by using libraries of cDNAs, shRNAs, CRISPR guide RNAs, or genetic suppressor elements (GSEs), or randomly throughout the genome using chemical or insertional mutagens, with each approach creating distinct genetic changes. The Validation-Based Insertional Mutagenesis (VBIM) strategy utilizes modified lentiviruses as insertional mutagens, placing strong promoters throughout the genome. Generating libraries with millions of cells carrying one or a few VBIM promoter insertions is straightforward, allowing selection of cells in which overexpression of VBIM-driven RNAs or proteins promote the phenotype of interest. VBIM-driven RNAs may encode full-length proteins, truncated proteins (which may have wild-type, constitutive, or dominant-negative activity), or antisense RNAs that can disrupt gene expression. The diversity in VBIM-driven changes allows for the identification of both gain-of-function and loss-of-function mutations in a single screen. Additionally, VBIM can target any genomic locus, regardless of whether it is expressed in the cells under study or known to have a biological function, allowing for true whole-genome screens without the complication and cost of constructing, maintaining, and delivering a comprehensive library. Here, we review the VBIM strategy and discuss examples in which VBIM has been successfully used in diverse screens to identify novel genes or novel functions for known genes. In addition, we discuss considerations for transitioning the VBIM strategy to in vivo screens. We hope that other laboratories will be encouraged to use the VBIM strategy to identify genes that influence their phenotypes of interest. © 2022 Wiley Periodicals LLC.

Indexed as

Genetic TestingLentivirusMutagenesis, InsertionalMutationPhenotypecell librariesdrug resistanceforward geneticsinsertional mutagenesisin vivo screenslentiviral vectors

Identifiers

PMID35316583
PMCPMC8969887
OpenAlexW4220653432

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.